|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
7 Clarke Dr, Cranbury, New Jersey 08512, US
|
|
Outlook Therapeutics, Inc. | 6,953 followers on LinkedIn. ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO | Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S.
|
Outlook Therapeutics, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Outlook Therapeutics, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Outlook Therapeutics, Inc. customer service number in your country click here to find.
Russ Trenary is the CEO of Outlook Therapeutics, Inc.. To contact Russ Trenary email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.